Calls
1
u/mister-pg
Reddit r/biotech_stocks
Win Rate
-
return
-
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 02
$7.19
-
The author argues Athira Pharma is deeply undervalued because its post-acquisition market cap (~$29M) is far below its ~$110M cash position while it now owns Phase 3 oncology drug Lasofoxifene. The investment mechanism is that positive Phase 2 PFS data for Lasofoxifene plus an upcoming mid-2027 Phase 3 ELAINE-3 readout should re-rate the stock, with added optionality from ATH-1105 ALS Phase 2 biomarker results in 2026. Author price targets are $12–15 by 2026, $35–45 by 2027 on Phase 3 success, and $75–100 by 2028–2030 on approval/M&A. The main stated risk is Phase 3 failure, which could send the stock back to ~$4.00 cash-shell value.
Other
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/mister-pg has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: ATHA.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
